324 related articles for article (PubMed ID: 11220652)
21. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
22. Carcinogen biomarkers for lung or oral cancer chemoprevention trials.
Hecht SS
IARC Sci Publ; 2001; 154():245-55. PubMed ID: 11220664
[TBL] [Abstract][Full Text] [Related]
23. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
24. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
25. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers in upper aerodigestive tract tumorigenesis: a review.
Shin DM; Hittelman WN; Hong WK
Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):697-709. PubMed ID: 7881344
[TBL] [Abstract][Full Text] [Related]
27. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
28. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
29. Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Ranger-Moore J; Alberts DS; Montironi R; Garcia F; Davis J; Frank D; Brewer M; Mariuzzi GM; Bartels HG; Bartels PH
Eur J Cancer; 2005 Sep; 41(13):1875-88. PubMed ID: 16087328
[TBL] [Abstract][Full Text] [Related]
30. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Lippman SM; Heymach JV
Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
[TBL] [Abstract][Full Text] [Related]
31. Development of cancer chemopreventive drugs based on mechanistic approaches.
Steele VE; Kelloff GJ
Mutat Res; 2005 Dec; 591(1-2):16-23. PubMed ID: 16083917
[TBL] [Abstract][Full Text] [Related]
32. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
33. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
Meyskens FL
IARC Sci Publ; 2001; 154():49-55. PubMed ID: 11220668
[TBL] [Abstract][Full Text] [Related]
34. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
[TBL] [Abstract][Full Text] [Related]
35. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
36. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
Christov K; Grubbs CJ; Shilkaitis A; Juliana MM; Lubet RA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5488-96. PubMed ID: 17875779
[TBL] [Abstract][Full Text] [Related]
37. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer.
Tao L; Wang W; Kramer PM; Lubet RA; Steele VE; Pereira MA
Mol Carcinog; 2004 Feb; 39(2):79-84. PubMed ID: 14750212
[TBL] [Abstract][Full Text] [Related]
38. Data evaluation as a contribution to cancer prevention.
Stewart BW
IARC Sci Publ; 1996; (139):303-12. PubMed ID: 8923040
[TBL] [Abstract][Full Text] [Related]
39. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
40. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.
Scott EN; Gescher AJ; Steward WP; Brown K
Cancer Prev Res (Phila); 2009 Jun; 2(6):525-30. PubMed ID: 19470784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
